Biotech Stocks

Track and analyze companies developing breakthrough therapies and innovative biotechnology solutions

# Company Price Market Cap Biotech Angle Tags
1
Amgen Inc.
AMGN
$291.16 $156.51B Leading biologic medicines developer Oncology Immunology Cardiovascular
2
Gilead Sciences, Inc.
GILD
$104.08 $129.71B Antiviral and oncology therapeutics HIV Oncology Cell Therapy
3
Vertex Pharmaceuticals Incorporated
VRTX
$459 $118.21B Cystic fibrosis treatments leader Rare Disease Gene Editing Pipeline
4
Regeneron Pharmaceuticals, Inc.
REGN
$673.6 $72.42B Antibody therapeutics platform Immunology Oncology Eye Disease
5
Seagen Inc.
SGEN
$228.74 $43.15B Antibody-drug conjugate technology Oncology ADC Pipeline
6
Alnylam Pharmaceuticals, Inc.
ALNY
$256.45 $33.08B RNAi therapeutics pioneer RNAi Rare Disease Pipeline
7
BioNTech SE
BNTX
$119.83 $28.73B mRNA and immunotherapy platform mRNA Oncology Vaccines
8
BeiGene, Ltd.
BGNE
$184.71 $20.21B Global oncology therapeutics Oncology China Pipeline
9
Incyte Corporation
INCY
$70.42 $13.63B JAK inhibitors and oncology Oncology Immunology JAK
10
Moderna, Inc.
MRNA
$32.99 $12.70B mRNA therapeutics platform mRNA Vaccines Oncology
11
Sarepta Therapeutics, Inc.
SRPT
$107.95 $10.31B Genetic medicine for rare diseases Gene Therapy Rare Disease DMD
12
CRISPR Therapeutics AG
CRSP
$49.72 $4.26B CRISPR gene editing platform Gene Editing CRISPR Pipeline
13
Recursion Pharmaceuticals, Inc.
RXRX
$10.53 $4.04B AI-powered drug discovery AI Platform Pipeline
14
Denali Therapeutics Inc.
DNLI
$21.37 $3.08B Neurodegenerative disease focus Neurology Pipeline Protein
15
Beam Therapeutics Inc.
BEAM
$32.4 $2.68B Base editing technology Gene Editing Base Editing Pipeline
16
Kymera Therapeutics, Inc.
KYMR
$36.88 $2.39B Protein degradation platform Protein Oncology Pipeline
17
Arvinas, Inc.
ARVN
$18.31 $1.26B Protein degradation therapeutics Protein Oncology Pipeline
18
Intellia Therapeutics, Inc.
NTLA
$10.7 $1.09B In vivo CRISPR therapeutics Gene Editing CRISPR Pipeline
19
AbCellera Biologics Inc.
ABCL
$3.27 $965.85M AI-powered antibody discovery AI Antibodies Platform
20
Intercept Pharmaceuticals, Inc.
ICPT
$19 $794.69M Liver disease therapeutics Liver NASH Pipeline
21
Fate Therapeutics, Inc.
FATE
$1.42 $161.73M Cell therapy platform Cell Therapy Oncology Pipeline
22
Editas Medicine, Inc.
EDIT
$1.38 $113.92M CRISPR gene editing therapies Gene Editing CRISPR Pipeline
23
bluebird bio, Inc.
BLUE
$7.27 $70.68M Gene therapy for rare diseases Gene Therapy Rare Disease Pipeline
24
Arena Pharmaceuticals, Inc.
ARNA
$99.99 $- Small molecule therapeutics Small Molecule Pipeline Immunology

A lot of concern around Moderna over next year or so, says Jefferies Michael Yee

Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.

News image

Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129707&wire=1 or contact Joseph E. Levi, Esq.

News image

AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.

News image

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and certain of its officers.

News image

Moderna, Inc.: Working Hard But Competition Is Working Harder

MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.

News image

Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

News image

Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129654&wire=1 or contact Joseph E. Levi, Esq.

News image

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230.

News image

Moderna (MRNA) Q4 2024 Earnings Call Transcript

Moderna (NASDAQ:MRNA ) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Ellie Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Tyler Van Buren - TD Cowen Luca Issi - RBC Capital Courtney Breen - Bernstein Edward Tenthoff - Piper Sandler Jessica Fye - J.P. Morgan Simon Baker - Redburn Atlantic Myles Minter - William Blair Tim Anderson - Bank of America Operator Good day, and thank you for standing by.

News image

Moderna shares rise on quarterly revenue beat despite wider-than-expected loss

Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported a wider-than-expected loss per share of $2.91, compared to estimates of a loss per share of $2.73.

News image

Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Feb. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) have opportunity to lead the securities fraud class action lawsuit.

News image

Moderna's Q4 Loss Wider Than Expected

Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.

News image

Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) should contact Levi & Korsinsky about pending Class Action - REGN

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129622&wire=1 or contact Joseph E. Levi, Esq.

News image

Moderna has no 'visible path' to profitability, analyst says

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight.

News image

Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.

News image

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.

LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.

News image

Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129601&wire=1 or contact Joseph E. Levi, Esq.

News image

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.

News image

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.

News image

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News image

MRNA Reiterates Guidance, Bird Flu Vaccine in Pipeline

Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-19 pandemic.

News image

Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.

News image

Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129461&wire=1 or contact Joseph E. Levi, Esq.

News image

REGN Shareholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

News image

Moderna beats on revenue but loses more than expected as it scales down manufacturing

Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine.  It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.

News image

Moderna's wider-than-expected loss and soft guidance weigh on battered stock

COVID-19 vaccine sales topped consensus but RSV sales remain modest

News image

Moderna posts bigger loss than expected as vaccine maker scales down manufacturing

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.

News image

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage pipeline and cost reduction efforts.

News image

The Ultimate Healthcare Stock to Buy With $500 Right Now

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

News image

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN

NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.

News image

Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

News image

Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.

News image

Alnylam: Waiting For Regulatory Updates In March

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.

News image

Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129372&wire=1 or contact Joseph E. Levi, Esq.

News image

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

News image

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129361&wire=1 or contact Joseph E. Levi, Esq.

News image

Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share.

News image

What Makes BioNTech (BNTX) a New Buy Stock

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News image

March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.

News image

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO Tolga Tanguler - Chief Commercial Officer Pushkal Garg - CMO Jeff Poulton - CFO Christine Lindenboom - Chief Corporate Communications Officer Conference Call Participants Tazeen Ahmad - Bank of America Kostas Biliouris - BMO Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies Ritu Baral - TD Cowen Teraesa Vitelli - Scotiabank Gary Nachman - Raymond James Jessica Fye - JPMorgan Paul Matteis - Stifel Salveen Richter - Goldman Sachs Ellie Merle - UBS Mani Foroohar - Leerink Partners Luca Issi - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Fourth Quarter Full Year 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

News image

Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129320&wire=1 or contact Joseph E. Levi, Esq.

News image

Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.

News image

Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News image

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News image

March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129263&wire=1 or contact Joseph E. Levi, Esq.

News image

Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a year ago.

News image

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129204&wire=1 or contact Joseph E. Levi, Esq.

News image

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

News image

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can b.

News image

Frequently Asked Questions

Biotechnology applications include:
  • Therapeutics - Novel drug development
  • Gene Therapy - Genetic disease treatment
  • Cell Therapy - Cellular treatments
  • Immunotherapy - Immune system targeting
  • Precision Medicine - Personalized treatments

The leading biotech companies by market cap include:
  • AMGN - Amgen Inc.
  • GILD - Gilead Sciences, Inc.
  • VRTX - Vertex Pharmaceuticals Incorporated
  • REGN - Regeneron Pharmaceuticals, Inc.
  • SGEN - Seagen Inc.

Major segments include:
  • Oncology - Cancer treatments
  • Rare Diseases - Orphan drugs
  • Gene Editing - CRISPR and beyond
  • Immunology - Immune disorders
  • Neuroscience - Brain disorders

Key investment considerations include:
  • Breakthrough potential
  • Large market opportunities
  • Patent protection
  • M&A activity
  • Aging demographics

Key factors affecting biotech stocks include:
  • Clinical trial results
  • FDA approvals
  • Patent decisions
  • Market size
  • Competition
  • Funding environment